Study: Coffee Cuts Cancer Risk

Evidence presented at AACR suggests that daily coffee consumption may cut a person’s risk of developing a form of liver cancer.

Written byRina Shaikh-Lesko
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, ROB TAYLORA daily coffee routine may reduce a person’s risk of developing hepatocellular carcinoma (HCC), the most common form of liver cancer—and the higher the coffee intake, the lower the risk. V. Wendy Setiawan of the University of Southern California presented this unpublished finding at the American Association for Cancer Research (AACR) annual meeting held in San Diego, California, this week (April 9).

Setiawan and her colleagues enrolled nearly 180,000 participants from a variety of ethnic backgrounds in a long-term prospective study, and followed them for up to 18 years. Nearly 500 of the participants developed HCC. Overall, the study participants who reported drinking one to three cups of coffee per day had a 29 percent drop in HCC risk; those who drank four or more cups saw their risk of developing HCC drop by 42 percent.

“Now we can add HCC to the list of medical ailments, such as Parkinson’s disease, type 2 diabetes, and stroke, that may be prevented by coffee intake,” Setiawan said in a statement.

The association between coffee consumption and lowered cancer risk persisted even after the researchers controlled for ethnicity, gender, obesity, smoking, alcohol use, and diabetes.

“The roles of specific coffee components that are actually protective against HCC remain open to discussion,” Setiawan said. The researchers next plan to study whether the apparently protective effects of coffee hold up for other liver diseases.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies